Reuters logo
BRIEF-Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.
2017年9月11日 / 上午10点52分 / 10 天前

BRIEF-Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.

Sept 11 (Reuters) - Contravir Pharmaceuticals Inc:

* Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States

* Contravir Pharmaceuticals - ‍intends to initiate U.S.-based clinical trial for txl in q4 of 2017, pending approval by institutional review board​

* Contravir Pharmaceuticals - ‍ intends to initiate its first us-based clinical trial for txl in Q4 2017, pending approval by institutional review board​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below